Growth Metrics

Moderna (MRNA) Income from Continuing Operations (2017 - 2025)

Moderna (MRNA) has disclosed Income from Continuing Operations for 9 consecutive years, with 826000000.0 as the latest value for Q4 2025.

  • Quarterly Income from Continuing Operations rose 26.25% to 826000000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 2822000000.0 through Dec 2025, up 20.75% year-over-year, with the annual reading at 2822000000.0 for FY2025, 20.75% up from the prior year.
  • Income from Continuing Operations for Q4 2025 was 826000000.0 at Moderna, down from 200000000.0 in the prior quarter.
  • The five-year high for Income from Continuing Operations was 4868000000.0 in Q4 2021, with the low at 3630000000.0 in Q3 2023.
  • Average Income from Continuing Operations over 5 years is 473350000.0, with a median of 46000000.0 recorded in 2023.
  • The sharpest move saw Income from Continuing Operations soared 2476.07% in 2021, then crashed 1638.46% in 2025.
  • Over 5 years, Income from Continuing Operations stood at 4868000000.0 in 2021, then tumbled by 69.91% to 1465000000.0 in 2022, then plummeted by 85.19% to 217000000.0 in 2023, then plummeted by 616.13% to 1120000000.0 in 2024, then rose by 26.25% to 826000000.0 in 2025.
  • According to Business Quant data, Income from Continuing Operations over the past three periods came in at 826000000.0, 200000000.0, and 825000000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.